Organized by the Cross Company Abuse Liability Council (CCALC) • With scientific support from FDA • Participation by FDA and NIDA (National Institute on Drug Abuse) representatives.
Topics related to preclinical and clinical methods to evaluate the abuse and dependence potential of CNS-active drugs. Focus on current challenges and further discussion of the 2017 FDA Guidance.
Oct 11: 8:30 am - 5:00 pm
Oct 12: 8:30 am - 1:30 pm
Reception: Oct 11: 5:30 - 7:00 pm
Hyatt Regency Bethesda
Use this link to book your room at a special meeting rate (limited rooms available at discounted rate through September 21st, first come first served).
General hotel information is below.
Use this link to register for the meeting. Advanced registration is requested. Registration fees will increase after